Helus Pharma's HLP004 Shows Promise in Phase 2 Anxiety Disorder Trial

Helus Pharma, the commercial operating name of Cybin Inc., has announced promising Phase 2 clinical trial results for its investigational drug HLP004, a novel serotonergic agonist (NSA) designed to treat generalized anxiety disorder (GAD). The study focused on adults with moderate-to-severe GAD who continued to experience symptoms despite standard antidepressant therapy. Patients receiving a 20 mg dose of HLP004 alongside their existing treatments demonstrated a statistically significant mean reduction of 10.4 points on the Hamilton Anxiety Rating Scale (HAM-A) after six weeks, with the results showing strong statistical significance (p<0.0001). The trial also reported durable response rates, favorable tolerability, and a short in-clinic treatment experience, positioning HLP004 as a potential breakthrough for a patient population with limited treatment options.

The company, which trades on NASDAQ as HELP and on the Cboe CA as HELP, is developing a portfolio of novel serotonergic agonists aimed at addressing serious mental health conditions through activation of serotonin pathways believed to promote neuroplasticity. Helus Pharma's pipeline includes HLP003, another proprietary NSA currently in Phase 3 development for major depressive disorder with Breakthrough Therapy Designation from the U.S. Food and Drug Administration, along with an extensive research portfolio of investigational NSAs. The company operates across Canada, the United States, the United Kingdom, and Ireland, with updates available through their corporate communications platform and specialized news distribution services like BioMedWire, which is part of the Dynamic Brand Portfolio within the InvestorBrandNetwork.

This development represents a significant advancement in mental health treatment, particularly for the substantial portion of GAD patients who don't achieve adequate relief from current standard-of-care therapies. The positive topline results from this signal detection study support continued development of HLP004, potentially offering a new therapeutic option that combines efficacy with a favorable safety profile. For more detailed information, readers can visit the full press release through the company's newsroom or explore the broader context of biotechnology developments through platforms like BioMedWire, which provides specialized coverage of the life sciences sector and maintains a comprehensive disclaimer regarding its content distribution practices.